Is Wegovy Safe for Long-Term Use? What the Clinical Evidence Shows

What the trial data established over 68 weeks and beyond

The STEP 1 trial (published in the New England Journal of Medicine) followed nearly 2,000 adults on semaglutide 2.4mg for 68 weeks. The side-effect pattern that emerged was consistent and, crucially, time-limited in its most troublesome phase. Nausea, vomiting, diarrhoea and constipation were the most frequently reported events, affecting a meaningful proportion of participants — but the peak of those symptoms clustered around the early weeks and each dose increase, not across the full treatment period.

Beyond STEP 1, the SELECT cardiovascular outcomes trial ran for a median of over three years and enrolled more than 17,000 adults. Its primary purpose was cardiovascular risk reduction, but the sustained safety data it generated (reviewed by the MHRA as part of the ongoing benefit-risk assessment) gave regulators confidence in the medicine's profile at the 2.4mg dose across extended follow-up. No new or unexpected serious safety signals emerged that reversed its licensed status. The NHS semaglutide medicines page summarises the known side-effect profile in patient-facing terms.

One misconception worth setting aside: some people assume that a medicine studied for 68 weeks has only 68 weeks of safety data behind it. In reality, semaglutide has been used for type 2 diabetes treatment for years longer than its weight-management licence, and that real-world post-marketing record feeds into the ongoing regulatory picture.

Side effects that warrant medical attention during long-term use

Most people who continue Wegovy beyond the escalation phase report the acute GI symptoms have quietened considerably. What matters for longer-term use is knowing which symptoms should prompt medical contact rather than watchful waiting.

Pancreatitis is the clearest example. In January 2026 the MHRA issued a Drug Safety Update specifically addressing GLP-1 medicines and acute pancreatitis, confirming it as a known but infrequent serious risk. The signal to act on is severe, persistent abdominal pain (particularly pain that radiates toward the back) with or without vomiting. That combination warrants stopping the injection and seeking urgent medical assessment, not managing it at home.

Other situations that need prompt attention include signs of gallbladder problems (right-sided upper abdominal pain, fever, jaundice), significant dehydration from persistent vomiting or diarrhoea that isn't resolving, and any allergic reaction. Changes in mood or thoughts of self-harm should also lead to immediate contact with a doctor or crisis service. For a full account of side effects by frequency and severity, our Wegovy side effects guide covers the complete profile, and the detail by symptom type is also covered for female-specific patterns where relevant evidence exists.

If you want to report a suspected side effect (or flag a suspicious seller) the MHRA Yellow Card scheme is open to patients and carers directly, not just clinicians.

How long-term use is monitored, and what stopping looks like

Safe long-term use isn't passive. Legitimate treatment involves periodic clinical review: weight response, tolerability at the current dose, any new health conditions, and medicines that might interact. NICE's recommendation for semaglutide under TA875 specifies a maximum of two years for NHS use within specialist services, with a review point at six months to assess whether weight response justifies continuing. Private prescribing doesn't carry that two-year ceiling by regulation, but the review principle is the same: continuing treatment should be clinically justified at each assessment.

Weight regain after stopping is a real and well-documented phenomenon. Studies following participants after discontinuation of semaglutide found that much of the lost weight returned within a year. This doesn't mean indefinite use is the right answer for everyone, but it does mean the decision to stop should be made with a prescriber rather than unilaterally, particularly around timing, any tapering discussion, and what lifestyle or other support is in place. Questions about what sustained use looks like in practice are worth raising at the consultation stage, before treatment starts. You can explore broader considerations on the question of staying on Wegovy long-term or read about semaglutide's long-term safety record in more detail.

How a prescriber assesses your specific risk profile

Population-level trial data tells you what happened across thousands of participants. What it can't tell you is your individual picture. A prescriber weighing long-term suitability looks at things the trials averaged out: your history of pancreatitis or gallbladder disease, any current medicines that slow gastric motility, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2, and whether you're using oral contraceptives that could be affected by altered absorption during the early weeks of treatment and each dose step.

At nume, every repeat order goes back to a GPhC-registered prescriber for clinical review. There are no auto-renewals. A prescriber reads your responses each time, not software. If you're considering starting Wegovy and want to talk through your specific medical history, start your free consultation and our clinical team will work through it with you. Our Wegovy treatment page covers what's included and how the process works.